Nabity Jensen Investment Management Inc Sells 1,497 Shares of Pfizer Inc. $PFE

Nabity Jensen Investment Management Inc cut its position in shares of Pfizer Inc. (NYSE:PFE) by 12.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,588 shares of the biopharmaceutical company’s stock after selling 1,497 shares during the quarter. Nabity Jensen Investment Management Inc’s holdings in Pfizer were worth $257,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter worth $27,000. North Capital Inc. bought a new position in shares of Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd bought a new stake in Pfizer in the 1st quarter worth about $28,000. Horizon Financial Services LLC bought a new stake in Pfizer in the 1st quarter worth about $35,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the 1st quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Bank of America lifted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Stock Performance

NYSE PFE opened at $25.46 on Wednesday. The firm has a market cap of $144.75 billion, a price-to-earnings ratio of 13.54, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $24.55 and a 200-day moving average price of $24.11. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.